Topic
Rapid eye movement sleep
About: Rapid eye movement sleep is a research topic. Over the lifetime, 3740 publications have been published within this topic receiving 183415 citations. The topic is also known as: REM sleep & REMS.
Papers published on a yearly basis
Papers
More filters
TL;DR: In PD, pramipexole improved parkinsonism but did not modify RBD related symptoms and objective video-polysomnographic abnormalities, suggesting that in PD, dopamine mechanisms do not play a central role in the pathogenesis of RBD.
Abstract: PARKINSON DISEASE (PD) IS A NEURODEGENERATIVE DISORDER ASSOCIATED WITH LOSS OF THE DOPAMINERGIC CELLS IN THE SUBSTANTIA NIGRA resulting in bradykinesia, tremor, and rigidity. These classical motor symptoms are responsive to dopaminergic agents. In PD, the degenerative process also involves non-dopaminergic neuronal areas beyond the substantia nigra such as the lower brainstem, the amygdala, and the cortex. Impairment of these brain areas in PD account for the occurrence of several non-motor symptoms, including dysautonomia and dementia, which do not respond to dopamine replacement therapy.1
REM sleep behavior disorder (RBD) is a frequent feature of PD that is characterized by dream-enacting behaviors, unpleasant dreams, and loss of muscle atonia during REM sleep.2,3 It is unknown if RBD in PD results from dopaminergic deficiency. To assess whether dopaminergic dysfunction plays a major role in the pathogenesis of RBD in PD, we prospectively examined the therapeutic effect of pramipexole, a D2-D3 dopamine receptor agonist, on RBD features in patients with PD.
98 citations
TL;DR: A functionally significant amount of 5HT is present in the extracellular space within the XII nucleus region, and its decrement during carbachol-induced, REM sleep-like atonia is likely to reflect that occurring during natural REM sleep; this may contribute to the decreased tone of upper airway muscles and airway patency.
98 citations
TL;DR: The results suggest that a GABAergic projection from the substantia nigra pars reticulata to the PPN could be involved in the control of REM with atonia, signs which indicate REM sleep.
98 citations
TL;DR: GHB administered before nocturnal or diurnal sleep increases stages 3 and 4 and decreases stage 1 non-rapid eye movement (NREM) sleep and slightly decreases REM latency when administered in the morning, and this effect is correlated with age.
Abstract: Gamma-hydroxybutyrate (GHB) is a drug currently used to treat narcolepsy. The present study documents its effect on sleep organization in healthy subjects. GHB and a placebo were given at bedtime and before a morning nap in a double-blind fashion. GHB administered before nocturnal or diurnal sleep increases stages 3 and 4 and decreases stage 1 non-rapid eye movement (NREM) sleep. In addition, GHB improves REM efficiency at night and reduces wake time after sleep onset when administered before a morning nap recording. GHB also slightly decreases REM latency when administered in the morning, and this effect is correlated with age. Hypotheses regarding mechanisms of action GHB and the involvement of hypothalamic structures in the regulation of REM sleep are discussed.
98 citations
TL;DR: State-dependent aspects of consciousness are explored with particular attention to waking and dreaming and an explanatory model is presented which states that neuromodulation, as well as input source and brain activation level differentiate states of the brain, while the self-organized collective neuronal oscillations unify consciousness via long range correlations.
97 citations